These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Search MEDLINE/PubMed


  • Title: [Regulatory effects of luteolin on airway inflammation in asthmatic rats].
    Author: Zeng W, Wu C, Dai Y.
    Journal: Zhonghua Yi Xue Za Zhi; 2014 Aug 26; 94(32):2535-9. PubMed ID: 25410928.
    Abstract:
    OBJECTIVE: To explore the regulatory effects of luteolin on airway inflammation in asthmatic rats. METHODS: A total of 48 male Sprague-Dawley (SD) rats were randomly divided into 3 groups of control, asthmatic and luteolin(n = 16 each). The rat model of bronchial asthma was established in asthmatic and luteolin groups. The model was induced by intraperitoneally injecting a mixture of ovalbumin and aluminum hydroxide at Day 1 and 8. After two weeks, aomization excitation of normal saline (containing 1% ovalbumin) was induced thrice weekly. The treatment lasted 8 weeks. In control group, the mixture of ovalbumin, aluminum hydroxide and normal saline containing 1% ovalbumin was replaced by normal saline. At 30 min after aomization excitation, normal saline was given to rats in control and asthmatic groups, while 1 mg/kg luteolin was given intraperitoneally to luteolin group. The inflammatory cell number and level of interleukin-4 (IL-4) were measured in bronchoalveolar lavage fluid (BALF). The histopathological changes were observed under light microscope. The activities of peroxisome proliferator-activated receptors (PPARγ) and p38 mitogen-activated protein kinases (p38MAPK) in pulmonary tissues were detected by immunohistochemistry and reverse transcription-polymerase chain reaction (RT-PCR). RESULTS: The bronchial wall thickness of asthma group, along with smooth muscle thickness ((93.3 ± 7.4), (34.9 ± 2.3) µm) was more than that of control ((61.9 ± 8.2), (19.3 ± 1.5) µm) and luteolin ((76.6 ± 6.7), (25.4 ± 4.6) µm) groups (all P < 0.05). The total cell count ((5.61 ± 0.63)×10(9)/L), neutrophil count ((1.83 ± 0.09)×10(9)/L), eosinophil count ((0.59 ± 0.09)×10(9)/L) and level of IL-4 ((78.23 ± 12.73) pg/ml) in BALF of asthmatic group were markedly higher than those of control ((1.53 ± 0.31)×10(9)/L, (0.45 ± 0.21)×10(9)/L, (0.07 ± 0.03) ×10(9)/L and (21.21 ± 2.53) pg/ml) and luteolin ((3.24 ± 0.25)×10(9)/L, (1.54 ± 0.10)×10(9)/L, (0.33 ± 0.05)×10(9)/L and (43.24 ± 8.65) pg/ml) groups (all P < 0.05). The results of semi-quantitative immunohistochemical analysis showed that the p38 protein level in control group (0.143 ± 0.017) and luteolin group (0.251 ± 0.021) was significantly less than that in asthmatic group (0.362 ± 0.008) (both P < 0.01). As compared with asthmatic group, the expression of PPARγ protein markedly increased (0.247 ± 0.034) in control (0.331 ± 0.056) and luteolin (0.442 ± 0.031) groups (all P < 0.05). The level of p38 mRNA in asthmatic group (0.718 ± 0.064) was significantly higher than that of control (0.312 ± 0.052) and luteolin (0.426 ± 0.067) groups (all P < 0.01). However, the PPARγ mRNA level in asthmatic group (0.266 ± 0.036) was much less than that in control (0.573 ± 0.042) and luteolin (0.687 ± 0.054) groups (all P < 0.01). CONCLUSION: The anti-inflammatory effects of luteolin may be associated with the regulation of PPARγ expression and p38MAPK signaling pathway in asthmatic rats.
    [Abstract] [Full Text] [Related] [New Search]